SNYNF supply chain intelligence for Sanofi: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Sanofi (SNYNF) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| DBVTF | DBV TECHNOLOGIES | 95% | Reciprocal relationship from DBVTF graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from DBVTF graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from DB… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 92% | Reciprocal relationship from ARWR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ARWR… |
| BMRN | BioMarin Pharmaceutical Inc. | 92% | Reciprocal relationship from BMRN graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from BMRN… |
| NVAX | Novavax, Inc. | 92% | Reciprocal relationship from NVAX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from NVAX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from NVAX… |
| REGN | Regeneron Pharmaceuticals, Inc. | 92% | Reciprocal relationship from REGN graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from REGN graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from REGN… |
| FULC | Fulcrum Therapeutics, Inc. | 90% | Reciprocal relationship from FULC graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from FULC graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from FULC… |
| MGNX | MacroGenics, Inc. | 85% | Reciprocal relationship from MGNX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from MGNX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from MGNX… |
| RXRX | Recursion Pharmaceuticals, Inc. | 85% | Reciprocal relationship from RXRX graph: mercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market, and sell our drug product candidates, and to … |
| ACIU | AC Immune SA | 72% | Reciprocal relationship from ACIU graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ACIU graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ACIU… |
| ACRS | Aclaris Therapeutics, Inc. | 72% | Reciprocal relationship from ACRS graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ACRS graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ACRS… |
| ADAG | Adagene Inc. | 72% | Reciprocal relationship from ADAG graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ADAG graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ADAG… |
| ALLR | Allarity Therapeutics, Inc. | 72% | Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ALNY graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ALNY… |
| ALXO | ALX Oncology Holdings Inc. | 72% | Reciprocal relationship from ALXO graph: ted by movements in our stock price that are beyond our control and therefore any declining value in our equity grants could negatively impact our ability to … |
| ANL | Adlai Nortye Ltd. | 72% | Reciprocal relationship from ANL graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ANL graph: asing by US$5 million as a result of advanced payments from customer. Investi… |
| ANRO | Alto Neuroscience, Inc. | 72% | Reciprocal relationship from ANRO graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ANRO graph: ts of preparing, filing, and prosecuting patent applications, maintaining a… |
| APGE | Apogee Therapeutics, Inc. | 72% | Reciprocal relationship from APGE graph: e technologies, products or programs. Even if these patents are granted, they may be difficult to enforce. Further, any issued patents that we may license or … |
| ARE | Alexandria Real Estate Equities, Inc. | 72% | Reciprocal relationship from ARE graph: er Technologies, Inc. 56.5 (4) 1,009,188 27,865 1.5 Baa1 BBB $ 178.6 10 Boston Children's Hospital 11.0 309,231 26,294 1.4 Aa2 AA $ — 11 Novartis AG 2.2 (5) 32… |
| ASND | Ascendis Pharma A/S | 72% | Reciprocal relationship from ASND graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ASND graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ASND… |
| ATOS | Atossa Therapeutics, Inc. | 72% | Reciprocal relationship from ATOS graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ATOS graph: pandemics, could seriously harm our future revenue and financial condition … |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: t of F-14 these relate to the Medicaid and state programmes with an adjustment in respect of prior year net US Product Sales in 2024 of 0.1 % (2023: 0.3 %; 202… |
| BBVA | Banco Bilbao Vizcaya Argentaria, S.A. | 72% | Reciprocal relationship from BBVA graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from BBVA graph: Item 4. Information on the Company—Business Overview—Supervision and Regula… |
| BDRX | Biodexa Pharmaceuticals Plc | 72% | Reciprocal relationship from BDRX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from BDRX graph: e downward pressure on health care costs in general, particularly prescript… |
| BIOA | BioAge Labs, Inc. | 72% | Reciprocal relationship from BIOA graph: ion of a new CDMO could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. In addi… |
| BLRX | BioLineRx Ltd. | 72% | Reciprocal relationship from BLRX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from BLRX graph: required to make under our in-licensing agreements is comprised of various … |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: ed March 31, Dollars in millions 2026 2025 Cost of products sold $ 16 $ 15 Selling, general and administrative 58 56 Research and development 72 72 Total stock… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from BM… |
| BNTX | BioNTech SE | 72% | Reciprocal relationship from BNTX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from BNTX… |
| CALC | CalciMedica, Inc. | 72% | Reciprocal relationship from CALC graph: vernmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter … |
| CBIO | Crescent Biopharma, Inc. | 72% | Reciprocal relationship from CBIO graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from CBIO graph: d parties or counterclaim against such third parties or negotiate more adva… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| FULC | Fulcrum Therapeutics, Inc. | 90% | Reciprocal relationship from FULC graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from FULC graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from FULC… |
| KYMR | Kymera Therapeutics, Inc. | 90% | Reciprocal relationship from KYMR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from KYMR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from KYMR… |
| ACRS | Aclaris Therapeutics, Inc. | 72% | Reciprocal relationship from ACRS graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ACRS graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ACRS… |
| ADAG | Adagene Inc. | 72% | Reciprocal relationship from ADAG graph: The Sanofi Agreement will remain effective until the expiration of the defined royalty on a product-by-product and country-by-country basis, unless terminated… |
| ALLR | Allarity Therapeutics, Inc. | 72% | Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the… |
| ANRO | Alto Neuroscience, Inc. | 72% | Reciprocal relationship from ANRO graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ANRO graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ANRO… |
| ATOS | Atossa Therapeutics, Inc. | 72% | Reciprocal relationship from ATOS graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ATOS graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ATOS… |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from AZN graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from AZN gr… |
| BDRX | Biodexa Pharmaceuticals Plc | 72% | Reciprocal relationship from BDRX graph: ticles like Midatech GNPs are emerging as the fastest growing sector within the nanomedicine market. The speed and nature of technological change means that p… |
| BLRX | BioLineRx Ltd. | 72% | Reciprocal relationship from BLRX graph: rsuant to the terms of a supply agreement to be negotiated in good faith with Bellerophon. See “— Out-Licensing Agreement with Bellerophon.” There can be no a… |
| BMRN | BioMarin Pharmaceutical Inc. | 72% | Reciprocal relationship from BMRN graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from BMRN… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from BMY graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from BMY gr… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from BM… |
| BNTX | BioNTech SE | 72% | Reciprocal relationship from BNTX graph: . Other collaboration programs have been progressed during the year ended December 31, 2020 and revenues of €52.1 million have been derived from deferred upfr… |
| CANF | Can-Fite BioPharma Ltd. | 72% | Reciprocal relationship from CANF graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from CANF graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from CANF… |
| CGEN | Compugen Ltd. | 72% | Reciprocal relationship from CGEN graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from CGEN graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from CGEN… |
| CLDX | Celldex Therapeutics, Inc. | 72% | Reciprocal relationship from CLDX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from CLDX… |
| CRVS | Corvus Pharmaceuticals, Inc. | 72% | Reciprocal relationship from CRVS graph: zed clinical trial in order to prioritize the development of our other two lead product candidates. Angel Pharmaceuticals is continuing the development of mup… |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from CTMX graph: tivities and efforts to establish and run clinical trials for CX-2051, CX-9… |
| CYTK | Cytokinetics, Incorporated | 72% | Reciprocal relationship from CYTK graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from CYTK graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from CYTK… |
| DBVT | DBV Technologies S.A. | 72% | Reciprocal relationship from DBVT graph: the Viaskin patch both biological and chemical substances. Viaskin is a Highly Scalable Manufacturing Technology We currently rely on a single contract manufa… |
| DBVTF | DBV TECHNOLOGIES | 72% | Reciprocal relationship from DBVTF graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from DBVTF graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from DB… |
| DNLI | Denali Therapeutics Inc. | 72% | Reciprocal relationship from DNLI graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from DNLI… |
| DNTH | Dianthus Therapeutics, Inc. | 72% | Reciprocal relationship from DNTH graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from DNTH graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from DNTH… |
| DRIO | DarioHealth Corp. | 72% | Reciprocal relationship from DRIO graph: panies are true competitors. Traditional Healthcare Systems and Health Plans While many health systems may have their own home-grown solutions for many of the… |
| EDIT | Editas Medicine, Inc. | 72% | Reciprocal relationship from EDIT graph: ents with third-party manufacturers to obtain finished drug products that are appropriately packaged for sale; • successful development of our internal manufa… |
| ELDN | Eledon Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ELDN graph: asures are also imposed by healthcare laws and regulations in international jurisdictions and in those jurisdictions we face the same issues as in the United … |
| ENLV | Enlivex Ltd. | 72% | Reciprocal relationship from ENLV graph: g other things, refusal to approve a pending application for a new drug product or biologic product, withdrawal of an approval, or suspension of production. A… |
| EQ | Equillium, Inc. | 72% | Reciprocal relationship from EQ graph: rotagonist Therapeutics, Inc., Sanofi SA, Takeda Pharmaceuticals, Teva Pharmaceuticals, Topas Therapeutics GmbH, and Zedira GmbH. Sales and Marketing Given our … |
| ESPR | Esperion Therapeutics, Inc. | 72% | Reciprocal relationship from ESPR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ESPR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ESPR… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| SNYNF-DEBT | Debt stack $23.3B | 90% | Market cache reports total debt of $23.3B. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| SNYNF-OWNER-DODGE-COX | Dodge & Cox | 90% | 13F overlay lists Dodge & Cox as top holder; 747 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| CMMB | Chemomab Therapeutics Ltd. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 1 | ['supplier'] |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| CMND | Clearmind Medicine Inc. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 1 | ['customer', 'supplier'] |
| BDRX | Biodexa Pharmaceuticals Plc | 100.00 | 2 | ['customer', 'supplier'] |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 100.00 | 2 | |
| BPTH | Bio-Path Holdings, Inc. | 100.00 | 2 | |
| BORAY | Bora Pharmaceuticals Co., Ltd. | 100.00 | 2 | |
| AUPH | Aurinia Pharmaceuticals Inc. | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 1 | ['supplier'] |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 |